Rather than asking drugmakers to shop around for CROs and CMOs separately, why not craft a one-stop shop? That's the thinking behind the partnership between Theorem Clinical Research and Gallus BioPharmaceuticals, as the two have agreed to share services.
The two companies didn't disclose financial terms, but the partnership works like this: Theorem, a CRO, will offer its services to Gallus' clients, while Gallus, a CMO, will produce treatments for Theorem's customers at its St. Louis manufacturing plant. The goal is to present an attractive, united front to clients, the companies said, speeding the path to market for treatments by creating a seamless system.
And the deal will benefit both companies, considering their complementary services. Theorem has offices in more than 30 countries, and CEO John Potthoff said in a statement that many of the company's overseas clients struggle to get a manufacturing foothold stateside. Under the Gallus partnership, however, Theorem's clients will have a full suite of production options, Potthoff said.
For Gallus, access to Theorem's client roster will only boost the company's early-stage manufacturing opportunities, President and CEO Mark Bamforth said, allowing Gallus to work with drugmakers from early-phase trials on through scale-up and commercial production. "With our new collaboration with Theorem, we'll be able to expand our portfolio of high quality services to meet more of the comprehensive demands of our customers," he said.
- read the companies' statement